Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Cancer Immunotherapy

Posts tagged ‘ESMO 2014 Live Blog’

Madrid – it’s Day 2 of the European Society for Medical Oncology (Twitter #ESMO14) annual meeting and the Congress is now in full swing. Today one of the highlights is the Presidential Session that takes place this afternoon. It’s where all attendees have the opportunity to hear what ESMO think is the most noteworthy data at the meeting, irrespective of the type of cancer.

Yesterday, we launched our Live ESMO blog series for Day 1, with commentary and insights posted throughout the day. If you missed the afternoon and evening notes, you can check them out.

Meanwhile, we’re really looking forward to hearing the CLEOPATRA trial overall survival (OS) data in HER2+ metastatic breast cancer at 4pm CET this afternoon.

CLEOPATRA (CLinical Evaluation Of Pertuzumab And TRAstuzumab) is an international, Phase III, randomised, double-blind, placebo-controlled study. The study evaluated the efficacy and safety profile of pertuzumab (Perjeta) combined with trastuzumab (Herceptin) and docetaxel chemotherapy compared to trastuzumab and chemotherapy plus placebo in 808 women with previously untreated HER2-positive metastatic breast cancer (mBC) or with HER2-positive mBC that that had recurred after prior therapy in the adjuvant or neo-adjuvant setting.

Sally wrote on Pharma Strategy Blog about the PFS data for the trial which was first presented at the 2011 San Antonio Breast Cancer Symposium (SABCS).

As Sally noted back in 2011, “the idea behind combining pertuzumab (Perjeta) and trastuzumab upfront is to enable a more comprehensive shut down of the HER2 pathway and delay resistance setting in.”

We’re now looking forward to the final overall survival data that will be presented for the first time at a conference by Dr Sandra Swain (Washington DC) in the Presidential Session at ESMO this afternoon.

There’s a press briefing between 8 and 9 where this data will be featured, so expect news releases to follow soon after this. Out of respect to researchers and those who come to these meetings to hear the data, we typically don’t write about data until after it’s been presented, so expect our initial commentary and analysis to follow later in the day on the blog.

What else are we looking out for at the Congress today and which sessions will the Mav be in? Subscribers can login in to read more or you can sign up below.

2 Comments

The 2014 European Society for Medical Oncology (ESMO) Congress starts this weekend in Madrid, and it finally feels like it is starting to take off with the release today at lunch-time in Europe of the oral abstracts (with the exception of late breakers) to be presented at the meeting.

This blog post is a preview of some of the oral abstracts that caught my attention in a quick preview this afternoon while in Paris en-route to Madrid.

Air France Concorde CDGFollowing its success at ASCO (one subscriber told us it helped him schedule which sessions to attend, another that it enabled him to question his team on what was really hot at the meeting), we’ll be writing a daily blog on Saturday, Sunday and Monday from ESMO.

It’s going to be a live blog in the sense that we plan to regularly update it during the day, and it will include details of which sessions we are in and our initial impressions of data that catches our interest.

More in-depth posts will follow later.

Back to the oral abstracts, subscribers can login below to read about some of the abstracts that have caught my attention. If you are not yet a subscriber, we do hope you will consider joining what is an exclusive club.

If you can only afford to sign up for a quarter you’re in for a treat as in addition to ESMO we will be covering in person two other major medical meetings this fall, including ASH in San Francisco, and (for now) you still get to read all our previous coverage!!

PS: we’ve not mentioned the companies and products covered in this introduction, as that would make it too easy for non-subscribers, or those in the media who constantly ask us at conferences for story ideas… we all need an edge 🙂

error: Content is protected !!